Prof. Dr. Stefan Fröhling

Managing Director (in ch.), NCT Heidelberg
Head:
Molecular and Cellular Oncology

Phone: +49 6221 56-6990 / -6991
Fax: +49 6221 56-6967
E-mail: stefan.froehling@nct-heidelberg.de

Since April 2018, Professor Stefan Fröhling has been Acting Managing Director of NCT Heidelberg. In addition, he heads the Molecular and Cellular Oncology group at NCT/DKFZ. Stefan Fröhling’s research aims at providing as many patients as possible with individually tailored cancer treatments. As part of the NCT Precision Oncology Program (NCT POP), much of his work is centered on the development of tools for the comprehensive molecular and functional characterization of individual tumors, and the conception of clinical studies examining the efficacy of modern, molecularly targeted treatment approaches. In addition to his research in the precision oncology field, Stefan Fröhling particularly focuses on the biology of bone and soft-tissue sarcomas as well as acute forms of leukemia.

Since April 2018
Acting Managing Director, NCT Heidelberg

2012-present
Attending Physician, Department of Translational Oncology, NCT/German Cancer Research Center and Department of Medical Oncology, NCT/Heidelberg University Hospital

2011-2012
Attending Physician, Research Group Leader, Department of Hematology, Oncology, Rheumatology, Infectious Diseases, Ulm University Hospital

2009-2011
Fellow, Research Group Leader, Department of Hematology, Oncology, Rheumatology, Infectious Diseases, Ulm University Hospital

2005-2009
Postdoctoral Scientist, Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School

1999-2005
Fellow in Internal Medicine, Hematology, Oncology, Rheumatology, Infectious Diseases, Ulm University Hospital

1998-1999
Resident in Internal Medicine, Hematology, Oncology, Rheumatology, Heidelberg University Hospital

2011
Associate Professor (“Außerplanmäßige Professur”), Ulm University

2004

Assistant Professor (“Habilitation”), Ulm University

1999

Doctor of Medicine (“Promotion”), Heidelberg University

1992-1997
Heidelberg University Medical School, Germany

1990-1992
Marburg University Medical School, Germany

Since 2017
Sarcoma Alliance for Research through Collaboration (SARC)

Since 2014
German Interdisciplinary Sarcoma Group (GISG)

Since 2009
American Association for Cancer Research (AACR)

Since 2008
European Hematology Association (EHA)

Since 2001
American Society of Hematology (ASH)

2018
Uncommon Collaboration Award, Chordoma Foundation

2009-2011
Young Investigator Fellowship, European Hematology Association-José Carreras Leukämie-Stiftung

2005-2007
Research Fellowship, German Research Foundation

2004
Leukemia Research Award, Franziska Kolb Foundation

Andrea Fries

Secretariat
Phone: +49 6221 56-6762
Fax: +49 6221 56-6967
andrea.fries@nct-heidelberg.de

Dr. Eva Lempp

Executive Assistant
Phone: +49 6221 56-38229
Fax: +49 6221 56-6967
eva.lempp@nct-heidelberg.de

Dr. Monika Huber

NCT Network Coordinator
Phone: +49 6221 56-6794
Fax: +49 6221 56-6967
monika.huber@nct-heidelberg.de

Dr. Maria Rius

Personal Assistant to the Director
Phone: +49 6221 56-35898
Fax: +49 6221 56-6967
maria.rius@nct-heidelberg.de

Dr. Stefanie Rudolph

Scientific Coordinator
Phone: +49 6221 56-32875
Fax: +49 6221 56-6967
stefanie.rudolph@nct-heidelberg.de

  1. Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Bühler C, Di Marcantonio D, Martinez E, Göllner S, Wickenhauser C, Müller-Tidow C, Lutz C, Bullinger L, Milsom MD, Sykes SM, Fröhling S,* Scholl C.* RET-mediated autophagy suppression as targetable codependence in acute myeloid leukemia. Leukemia. Accepted for publication.
  2. Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Kleinheinz K, Schlesner M, Sieverling L, Klink B, Schröck E, Hoogenboezem RM, Kasper B, Heilig C, Egerer G, Wolf S, von Kalle C, Eils R, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG, Omlor G, Lehner B, Bauer S, Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Hutter B, Renner M, Hohenberger P, Scholl C, Fröhling S. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun 9:144, 2018.
  3. Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W,* Glimm H,* Fröhling S.* Mutant KIT as imatinibsensitive target in metastatic sinonasal carcinoma. Ann Oncol 8:142-148, 2017.
  4. Chudasama P, Renner M, Straub M, Mughal SS, Hutter B, Kosaloglu Z, Schweßinger R, Scheffler M, Alldinger I, Schimmack S, Persigehl T, Kobe C, Jäger D, von Kalle C, Schirmacher P, Beckhaus MK, Wolf S, Heining C, Gröschel S, Wolf J, Brors B, Weichert W, Glimm H, Scholl C, Mechtersheimer G, Specht K, Fröhling S. Targeting FGFR1 for treatment of soft-tissue sarcoma. Clin Cancer Res 23:962-973, 2017.
  5. Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H,* Brummer T,* Fröhling S.* Cooperation of BRAF F595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia 30:937-946, 2016.
Prof. Dr. Stefan Fröhling